Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2018
Price : $35 *
At a glance
- Drugs CD40 ligand MUC1 loaded dendritic cell vaccine (Primary)
- Indications Adenocarcinoma; Breast cancer; Colon cancer; Lung cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions; First in man
- 05 Jun 2018 Results (n=18) assessing dose-escalation cohort in a phase 1 study of Ad-sig-hMUC-1/ecdCD40L vector vaccine, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 New source identified and integrated (ClinicalTrials.gov NCT02140996).
- 18 Aug 2014 New trial record